|Articles|November 3, 2014
Oncology Trial Times On the Increase
KMR Group recently assessed the duration of oncology trials and found a steady rise
Advertisement
KMR Group recently assessed the duration of oncology trials and found a steady rise in late stage oncology cycle times in the last 10 years. KMR Group assessed cycle time trends for more than 4,100 oncology trials using proprietary industry data across 32 companies and found that Phase II oncology trials require about one additional year, compared to trials conducted a decade ago. Phase III trials are taking almost five years, which is one and a half years longer than trials in 2003-2005. KMR defines study duration as the interval from protocol approval to database Lock.
Read the full release here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
2
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4